kidney cancer
Advertisement
Patients with CKD may experience a higher risk of cancer, so researchers examined whether this relationship may be causal.
In a phase 2 study, adding tivozanib to nivolumab did not show a benefit for renal cell carcinoma treatment.
The FDA granted Fast Track designation to ADI-270 for treating metastatic or advanced clear cell renal cell carcinoma.
What does the data and overall understanding of VEGF-TKIs tell us about which patients are optimal candidates for tivozanib?
Hypertension is a common adverse effect associated with the use of tyrosine kinase inhibitors (TKIs), such as axitinib. ...
In ESMO Open, Enrique Grande, MD, and collaborating researchers published findings from the IMMUNOSUN trial on the ...
Major organizations have issued guidelines for the treatment and management of kidney cancer that favor nephron-sparing ...
This week on DocWire, editors spoke with Giovanni Di Napoli, President of Medtronic Gastrointestinal, about GI Genius, ...
This week, findings from a clinical trial of children with high-risk Hodgkin lymphoma found the anti-CD30 antibody drug ...
New research from the Memorial Sloan Kettering Cancer Center and the Gustave Roussy Institute found that some patients ...
Renal cell carcinoma (RCC) is the most common histologic type of urologic cancer. Worldwide, the age-standardized rate ...
Several therapeutic combinations of immune-oncology (IO) plus vascular endothelial growth factor (VEGF) regimens have ...
Immune Checkpoint Therapy plus Cytoreductive Surgery in mRCC
...
Immune Checkpoint Inhibitor Response in Patients with mRCC
...
Costs of episodes of care in metastatic renal cell carcinoma (mRCC) vary by therapy and treatment decisions have ...
Ipilimumab plus nivolumab is a first-line combination treatment option in patients with metastatic renal cell carcinoma ...
Nivolumab plus ipilimumab was proven superior to sunitinib in objective response rate and overall survival in patients ...
Clinicians have used comprehensive genomic profiling to inform treatment selection in patients with metastatic renal ...
A study published in The Lancet Oncology found that pegilodecakin in combination with anti-PD-1 monoclonal antibody ...
A new study has found that patients with non-small cell lung cancer (NSCLC) and kidney cancer may benefit from ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.